Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic misoprostol plus oxytocin for prevention of postpartum hemorrhage in women with severe preeclampsia undergoing cesarean section
IRCT20201022049108N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (3 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Postoperative blood loss volume, Hemoglobin change and 1 more. Started Nov 2020; status: completed.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on IRCT20201022049108N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201022049108N1.